Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment

Please click here to see linked paper BackgroundTo investigate the potential predictors of response to regorafenib, in chemorefractory metastatic colorectal cancer (mCRC) patients with long-term efficacy from regorafenib treatment.MethodsRetrospective, single institution analysis of patients with ch...

Full description

Saved in:
Bibliographic Details
Published in:ESMO open 2017, Vol.2 (3), p.e000177-e000177, Article e000177
Main Authors: Martinelli, Erika, Sforza, Vincenzo, Cardone, Claudia, Capasso, Anna, Nappi, Anna, Martini, Giulia, Napolitano, Stefania, Rachiglio, Anna Maria, Normanno, Nicola, Cappabianca, Salvatore, Reginelli, Alfonso, Bisceglie, Maurizio Di, Latiano, Tiziana Pia, Maiello, Evaristo, Orditura, Michele, Vita, Fernando De, Morgillo, Floriana, Ciardiello, Fortunato, Troiani, Teresa
Format: Article
Language:English
Subjects:
biomarkers
epithelial–mesenchymal transition
Her-2
long responders
metastatic colorectal cancer
Original Research
regorafenib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Please click here to see linked paper BackgroundTo investigate the potential predictors of response to regorafenib, in chemorefractory metastatic colorectal cancer (mCRC) patients with long-term efficacy from regorafenib treatment.MethodsRetrospective, single institution analysis of patients with chemorefractory mCRC treated with regorafenib, in clinical practice setting. 123 patients were treated and stratified into two groups according to number of cycles received (
ISSN:2059-7029
2059-7029
DOI:10.1136/esmoopen-2017-000177